Skip to main content
Top
Published in: Clinical and Experimental Nephrology 2/2017

01-04-2017 | Original Article

Comparison of methods of steroid administration combined with tonsillectomy for IgA nephropathy patients

Authors: Hirofumi Watanabe, Shin Goto, Daisuke Kondo, Takuma Takata, Hajime Yamazaki, Michihiro Hosojima, Suguru Yamamoto, Yoshikatsu Kaneko, Ryuji Aoyagi, Ichiei Narita

Published in: Clinical and Experimental Nephrology | Issue 2/2017

Login to get access

Abstract

Background

IgA nephropathy (IgAN) is a chronic glomerular disease that causes end-stage renal disease in 20–40 % of patients within 20 years. The efficacy of tonsillectomy combined with steroid pulse (SP) administration (TSP) for clinical remission of IgAN has been reported. Particularly in Japan, TSP has been performed widely. However, the optimum method for steroid administration in TSP has not been established.

Methods

We retrospectively compared clinical remission in IgAN patients treated with tonsillectomy combined with two different steroid administration methods: (1) three courses of SP therapy and oral prednisolone administered on alternate days (group 3A; n = 25); and (2) one course of SP therapy and oral prednisolone administered on consecutive days (group 1C; n = 22).

Results

There was no significant difference in the clinical remission rates between the two groups at 12 (48.0 vs. 40.9 %, P = 0.77) and 24 months after starting treatment (68.0 vs. 72.7 %, P = 0.76) and at the final observation (76.0 vs. 81.8 %, P = 0.73). The mean period from starting treatment to remission of hematuria in group 3A was significantly shorter than that in group 1C (5.7 ± 4.4 vs. 9.9 ± 5.9 months, P = 0.03). Dyslipidemic patients treated for the first time with statin after the SP therapy were more present in group 3A at 24 months (P = 0.02).

Conclusions

In IgAN patients, treatment of group 3A may be effective for inducing rapid remission of hematuria. Further studies are needed to establish an appropriate protocol for TSP.
Literature
2.
go back to reference Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis. 1997;29:526–32.CrossRefPubMed Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis. 1997;29:526–32.CrossRefPubMed
3.
go back to reference Moriyama T, Tanaka K, Iwasaki C, et al. Prognosis in IgA nephropathy: 30-year analysis of 1012 patients at a single center in Japan. PLoS One. 2014;9:e91756.CrossRefPubMedPubMedCentral Moriyama T, Tanaka K, Iwasaki C, et al. Prognosis in IgA nephropathy: 30-year analysis of 1012 patients at a single center in Japan. PLoS One. 2014;9:e91756.CrossRefPubMedPubMedCentral
4.
go back to reference Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883–7.CrossRefPubMed Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883–7.CrossRefPubMed
5.
go back to reference Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15:157–63.CrossRefPubMed Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15:157–63.CrossRefPubMed
6.
go back to reference Xie Y, Nishi S, Ueno M, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int. 2003;63:1861–7.CrossRefPubMed Xie Y, Nishi S, Ueno M, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int. 2003;63:1861–7.CrossRefPubMed
7.
go back to reference Hotta O, Miyazaki M, Furuta T, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.CrossRefPubMed Hotta O, Miyazaki M, Furuta T, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.CrossRefPubMed
8.
go back to reference Miura N, Imai H, Kikuchi S, et al. Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol. 2009;13:460–6.CrossRefPubMed Miura N, Imai H, Kikuchi S, et al. Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol. 2009;13:460–6.CrossRefPubMed
9.
go back to reference Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008;3:1301–7.CrossRefPubMedPubMedCentral Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008;3:1301–7.CrossRefPubMedPubMedCentral
10.
go back to reference Ochi A, Moriyama T, Takei T, Uchida K, Nitta K. Comparison between steroid pulse therapy alone and in combination with tonsillectomy for IgA nephropathy. Int Urol Nephrol. 2013;45:469–76.CrossRefPubMed Ochi A, Moriyama T, Takei T, Uchida K, Nitta K. Comparison between steroid pulse therapy alone and in combination with tonsillectomy for IgA nephropathy. Int Urol Nephrol. 2013;45:469–76.CrossRefPubMed
11.
go back to reference Nakagawa N, Kabara M, Matsuki M, et al. Retrospective comparison of the efficacy of tonsillectomy with and without steroid-pulse therapy in IgA nephropathy patients. Intern Med. 2012;51:1323–8.CrossRefPubMed Nakagawa N, Kabara M, Matsuki M, et al. Retrospective comparison of the efficacy of tonsillectomy with and without steroid-pulse therapy in IgA nephropathy patients. Intern Med. 2012;51:1323–8.CrossRefPubMed
12.
go back to reference Kawamura T, Yoshimura M, Miyazaki Y, et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant. 2014;29:1546–53.CrossRefPubMedPubMedCentral Kawamura T, Yoshimura M, Miyazaki Y, et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant. 2014;29:1546–53.CrossRefPubMedPubMedCentral
13.
14.
go back to reference Kamei D, Moriyama T, Takei T, Wakai S, Nitta K. Comparison between consecutive and intermittent steroid pulse therapy combined with tonsillectomy for clinical remission of IgA nephropathy. Clin Exp Nephrol. 2014;18:320–8.CrossRefPubMed Kamei D, Moriyama T, Takei T, Wakai S, Nitta K. Comparison between consecutive and intermittent steroid pulse therapy combined with tonsillectomy for clinical remission of IgA nephropathy. Clin Exp Nephrol. 2014;18:320–8.CrossRefPubMed
15.
go back to reference Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534–45.CrossRefPubMed Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534–45.CrossRefPubMed
16.
go back to reference Kawamura T, Joh K, Okonogi H, et al. A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. J Nephrol. 2013;26:350–7.CrossRefPubMed Kawamura T, Joh K, Okonogi H, et al. A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. J Nephrol. 2013;26:350–7.CrossRefPubMed
17.
go back to reference Clinical guides for immunoglobulin A (IgA) nephropathy in Japan, third version. Nihon Jinzo Gakkai Shi. 2011;53:123–35. Clinical guides for immunoglobulin A (IgA) nephropathy in Japan, third version. Nihon Jinzo Gakkai Shi. 2011;53:123–35.
18.
go back to reference Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed
19.
go back to reference Suzuki Y, Matsuzaki K, Suzuki H, et al. Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol. 2013;18:481–6.CrossRefPubMed Suzuki Y, Matsuzaki K, Suzuki H, et al. Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol. 2013;18:481–6.CrossRefPubMed
20.
go back to reference Hotta O. Use of corticosteroids, other immunosuppressive therapies, and tonsillectomy in the treatment of IgA nephropathy. Semin Nephrol. 2004;24:244–55.CrossRefPubMed Hotta O. Use of corticosteroids, other immunosuppressive therapies, and tonsillectomy in the treatment of IgA nephropathy. Semin Nephrol. 2004;24:244–55.CrossRefPubMed
21.
go back to reference Moreno JA, Yuste C, Gutiérrez E, et al. Haematuria as a risk factor for chronic kidney disease progression in glomerular diseases: a review. Pediatr Nephrol. 2016;31:523–33.CrossRefPubMed Moreno JA, Yuste C, Gutiérrez E, et al. Haematuria as a risk factor for chronic kidney disease progression in glomerular diseases: a review. Pediatr Nephrol. 2016;31:523–33.CrossRefPubMed
22.
go back to reference Gutiérrez E, González E, Hernández E, et al. Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy. Clin J Am Soc Nephrol. 2007;2:51–7.CrossRefPubMed Gutiérrez E, González E, Hernández E, et al. Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy. Clin J Am Soc Nephrol. 2007;2:51–7.CrossRefPubMed
23.
go back to reference Goto M, Wakai K, Kawamura T, Ando M, Endoh M, Tomino Y. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant. 2009;24:3068–74.CrossRefPubMedPubMedCentral Goto M, Wakai K, Kawamura T, Ando M, Endoh M, Tomino Y. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant. 2009;24:3068–74.CrossRefPubMedPubMedCentral
24.
25.
go back to reference Suzuki Y, Matsuzaki K, Suzuki H, et al. Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clin Exp Nephrol. 2014;18:770–7.CrossRefPubMedPubMedCentral Suzuki Y, Matsuzaki K, Suzuki H, et al. Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clin Exp Nephrol. 2014;18:770–7.CrossRefPubMedPubMedCentral
27.
go back to reference Tanaka K, Moriyama T, Iwasaki C, Takei T, Nitta K. Effect of hematuria on the outcome of IgA nephropathy with mild proteinuria. Clin Exp Nephrol. 2015;19:815–21.CrossRefPubMed Tanaka K, Moriyama T, Iwasaki C, Takei T, Nitta K. Effect of hematuria on the outcome of IgA nephropathy with mild proteinuria. Clin Exp Nephrol. 2015;19:815–21.CrossRefPubMed
28.
go back to reference Coppo R. Is a legacy effect possible in IgA nephropathy? Nephrol Dial Transplant. 2013;28:1657–62.CrossRefPubMed Coppo R. Is a legacy effect possible in IgA nephropathy? Nephrol Dial Transplant. 2013;28:1657–62.CrossRefPubMed
29.
go back to reference Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001;110:434–7.CrossRefPubMed Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001;110:434–7.CrossRefPubMed
30.
go back to reference Kawaguchi T, Ieiri N, Yamazaki S, et al. Clinical effectiveness of steroid pulse therapy combined with tonsillectomy in patients with immunoglobulin A nephropathy presenting glomerular haematuria and minimal proteinuria. Nephrology (Carlton). 2010;15:116–23.CrossRefPubMed Kawaguchi T, Ieiri N, Yamazaki S, et al. Clinical effectiveness of steroid pulse therapy combined with tonsillectomy in patients with immunoglobulin A nephropathy presenting glomerular haematuria and minimal proteinuria. Nephrology (Carlton). 2010;15:116–23.CrossRefPubMed
32.
go back to reference Tatematsu M, Yasuda Y, Morita Y, et al. Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy. Clin Exp Nephrol. 2012;16:883–91.CrossRefPubMed Tatematsu M, Yasuda Y, Morita Y, et al. Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy. Clin Exp Nephrol. 2012;16:883–91.CrossRefPubMed
Metadata
Title
Comparison of methods of steroid administration combined with tonsillectomy for IgA nephropathy patients
Authors
Hirofumi Watanabe
Shin Goto
Daisuke Kondo
Takuma Takata
Hajime Yamazaki
Michihiro Hosojima
Suguru Yamamoto
Yoshikatsu Kaneko
Ryuji Aoyagi
Ichiei Narita
Publication date
01-04-2017
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 2/2017
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-016-1282-8

Other articles of this Issue 2/2017

Clinical and Experimental Nephrology 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.